Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aragen Bioscience, UTS Enter MoU | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Aragen Bioscience, UTS Enter MoU

Collaboration is to support and accelerate biologics R&D in Australia

By: Tiffany Coppolino

Aragen Bioscience, a fully owned subsidiary of GVK BIO and a large molecule CRO, and University of Technology Sydney (UTS), a university in Australia, have formed a collaboration to accelerate biologics R&D in Australia.
 
This partnership between UTS and Aragen unites the capabilities, experience, and expertise of two leading organizations to assist the Australian biopharma and biotech industries advance their ideas into medicines.
 
“Under this collaboration, customers can leverage Aragen’s proprietary, cutting edge, royalty-free CHO DG-44 expression system for therapeutic antibody production,” said Axel Schleyer, chief executive officer, Aragen Bioscience. “Downstream clinical development and manufacturing requirements can be met through UTS’s Biologics Innovation Facility (BIF), providing the Australian Biopharmaceutical Industry with a seamless solution from Concept through Clinic.”
 
“We are delighted to partner with one of the top Australian institutions—UTS, which has the infrastructure and knowhow to support large molecule clinical development,” said Manni Kantipudi, chairman, Aragen, and chief executive officer, GVK BIO. “The Aragen team is recognized globally for its antibody research, having discovered three Novel Biological Entities (NBEs) that are now commercial. Through this collaboration with UTS, we expect to support the local industry by bringing together knowhow, experience, and world class infrastructure that marries speed, innovation, and costs.”
 
UTS Faculty of Science business development manager, Andrew Groth, said “UTS welcomes the strategic partnership with Aragen to provide comprehensive but affordable cell line and expression technology solutions to Australian research communities and start-ups, to tackle the critical bottleneck during pre- and early-clinical stages of biologics development.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics